Roche pays Innovent Biologics $80M upfront for DLL3-targeting antibody-drug conjugate IBI3009 for small cell lung cancer, ...

Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials ...

Hutchmed sells 45% stake in Shanghai venture for $608M, Xgene's pain drug succeeds in Phase 2b, Hookipa buys Poolbeg Pharma, and Capricor gets $10M from Nippon Shinyaku.

Nine-figure financings dominated biotech's venture funding landscape, with 96 such rounds tallied by Endpoints News. The bevy of megarounds drowned out smaller ...